The Patent Finder

Methods of Treating Psoriasis Using IL-17 Antibody

Novartis Pharma AG

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 6 of these applications claim priority to application PCT/EP2011/067522, filed Oct 7, 2011. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
PatentTitleHolderStatusExpiresTime remainingConfidence
US 12,551,554Methods of Treating Chronic Inflammatory Disease with Secukinumab
In force
 · Medium confidence
Novartis Pharma AGIn force
Medium confidence
US 12,594,331Methods of Treating Psoriasis with Secukinumab
In force
 · Medium confidence
Novartis Pharma AGIn force
Medium confidence
US 12,594,332Methods of Treating Psoriasis with Secukinumab
In force
 · Medium confidence
Novartis Pharma AGIn force
Medium confidence
US 10,583,190Methods of Treating Psoriasis Using IL-17 Antibodies
In force
 · Medium confidence
Novartis Pharma AGIn force
Medium confidence
US 11,534,490Methods of Treating Psoriasis Using IL-17 Antagonists
In force
 · Medium confidence
Novartis Pharma AGIn force
Medium confidence
US 9,717,791Methods of Treating Psoriasis Using IL-17 Antibody
In force
 · High confidence
Novartis Pharma AGIn force
High confidence
Application 18/061,227Methods of Treating Psoriasis Using IL-17 Antagonists
Pending
Not granted
Novartis Pharma AGPendingNot granted
7 of 7 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
6 of these are in force and held by Novartis Pharma AG.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited